Epithelial tight junction proteins as potential antibody targets for pancarcinoma therapy

Cancer Immunology, Immunotherapy

Volumn 54, Issue 5, 2005, Pages 431-445

  Offner, Sonja ^a   Hekele, Armin ^b   Teichmann, Ulrike ^a   Weinberger, Susanne ^a   Gross, Susanne ^a   Kufer, Peter ^a   Itin, Christian ^a   Baeuerle, Patrick A ^a   Kohleisen, Birgit ^a  

^a MICROMET AG   (Germany)

^b UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

Antibody; Carcinoma; Claudin; Gene expression; Therapeutic target; Tight junction

Indexed keywords

ANTIBODY; CLAUDIN; CLAUDIN 1; CLAUDIN 3; CLAUDIN 4; CLAUDIN 7; CLAUDIN 8; IMMUNOGLOBULIN G; MESSENGER RNA; POLYCLONAL ANTIBODY; UNCLASSIFIED DRUG;

ANTIGEN BINDING; ANTIGEN RECOGNITION; ARTICLE; BONE MARROW BIOPSY; BREAST CANCER; CANCER CELL CULTURE; CANCER THERAPY; CARCINOMA; CARCINOMA CELL; COLON CARCINOMA; EPITHELIUM; FLUORESCENCE ACTIVATED CELL SORTING; HUMAN; HUMAN CELL; IMMUNOCYTOCHEMISTRY; KIDNEY CARCINOMA; NUCLEOTIDE SEQUENCE; PANCREAS CANCER; PRIORITY JOURNAL; PROTEIN DOMAIN; PROTEIN EXPRESSION; PROTEIN TARGETING; TIGHT JUNCTION;

AMINO ACID SEQUENCE; ANTIBODIES, MONOCLONAL; ANTIBODIES, NEOPLASM; ANTIGENS, NEOPLASM; CARCINOMA; CELL LINE, TUMOR; GENE EXPRESSION; GENE EXPRESSION PROFILING; HUMANS; IMMUNOGLOBULIN G; MEMBRANE PROTEINS; MOLECULAR SEQUENCE DATA; PROTEIN STRUCTURE, TERTIARY; SEQUENCE ALIGNMENT; TIGHT JUNCTIONS;

EID: 17444402091     PISSN: 03407004     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00262-004-0613-x     Document Type: Article

References (65)

1. Altschul SF, Gish W, Miller W, Myers EW, Lipman DJ (1990) Basic local alignment search tool. J Mol Biol 215:403-410
2. Apostolopoulos V, McKenzie IF (1994) Cellular mucins: targets for immunotherapy. Crit Rev Immunol 14:293-309
3. Arlt A, Vorndamm J, Muerkoster S, Yu H, Schmidt WE, Folsch UR, Schafer H (2002) Autocrine production of interleukin 1beta confers constitutive nuclear factor kappaB activity and chemoresistance in pancreatic carcinoma cell lines. Cancer Res 62:910-916
4. Bhattacharjee A, Richards WG, Staunton J, Li C, Monti S, Vasa P, Ladd C, Beheshti J, Bueno R, Gillette M, Loda M, Weber G, Mark EJ, Lander ES, Wong W, Johnson BE, Golub TR, Sugarbaker DJ, Meyerson M (2001) Classification of human lung carcinomas by mRNA expression profiling reveals distinct adenocarcinoma subclasses. Proc Natl Acad Sci U S A 98:13790-13795
5. Braun S, Hepp F, Sommer HL, Pantel K (1999) Tumor-antigen heterogeneity of disseminated breast cancer cells: implications for immunotherapy of minimal residual disease. Int J Cancer 84:1-5
6. Braun S, Pantel K, Müller P, Janni W, Hepp F, Kentenich CRM, Gastroph S, Wischnik A, Dimpfl T, Kindermann G, Riethmüller G, Schlimok G (2000) Cytokeratin-positive cells in the bone marrow and survival of patients with stage I, II, or III breast cancer. N Engl J Med 342:525-533
7. Chester KA, Mayer A, Bhatia J, Robson L, Spencer DI, Cooke SP, Flynn AA, Sharma SK, Boxer G, Pedley RB, Begent RH (2000) Recombinant anti- carcinoembryonic antigen antibodies for targeting cancer. Cancer Chemother Pharmacol 46(Suppl): S8-S12
8. Coleman M, Goldenberg DM, Siegel AB, Ketas JC, Ashe M, Fiore JM, Leonard JP (2003) Epratuzumab: targeting B-cell malignancies through CD22. Clin Cancer Res 9:3991S-3994S
9. Davis DM (2002) Assembly of the immunological synapse for T cells and NK cells. Trends Immunol 23:356-363
10. Di Paolo C, Willuda J, Kubetzko S, Lauffer I, Tschudi D, Waibel R, Pluckthun A, Stahel RA, Zangemeister-Wittke U (2003) A recombinant immunotoxin derived from a humanized epithelial cell adhesion molecule-specific single-chain antibody fragment has potent and selective antitumor activity. Clin Cancer Res 9:2837-2848
11. Fujita K, Katahira J, Horiguchi Y, Sonoda N, Furuse M, Tsukita S (2000) Clostridium perfringens enterotoxin binds to the second extracellular loop of claudin-3, a tight junction integral membrane protein. FEBS Lett 476:258-261
12. Furuse M, Fujita K, Hiiragi T, Fujimoto K, Tsukita S (1998) Claudin-1 and -2: novel integral membrane proteins localizing at tight junctions with no sequence similarity to occludin. J Cell Biol 141:1539-1550
13. Furuse M, Sasaki H, Fujimoto K, Tsukita S (1998) A single gene product, claudin-1 or -2, reconstitutes tight junction strands and recruits occludin in fibroblasts. J Cell Biol 143:391-401
14. Furuse M, Sasaki H, Tsukita S (1999) Manner of interaction of heterogeneous claudin species within and between tight junction strands. J Cell Biol 147:891-903
15. Gastl G, Spizzo G, Obrist P, Dunser M, Mikuz G (2000) EpCAM overexpression in breast cancer as a predictor of survival. Lancet 356:1981-1982
16. Ginaldi L, De Martinis M, Matutes E, Farahat N, Morilla R, Dyer MJ, Catovsky D (1998) Levels of expression of CD52 in normal and leukemic B and T cells: correlation with in vivo therapeutic responses to Campath-1H. Leuk Res 22:185-191
17. Goldenberg MM (1999) Trastuzumab, a recombinant DNA-derived humanized monoclonal antibody, a novel agent for the treatment of metastatic breast cancer. Clin Ther 21:309-318
18. Gonzalez-Mariscal L, Chavez de Ramirez B, Lazaro A, Cereijido M (1989) Establishment of tight junctions between cells from different animal species and different sealing capacities. J Membr Biol 107:43-56
19. Gottlinger HG, Funke I, Johnson JP, Gokel JM, Riethmuller G (1986) The epithelial cell surface antigen 17-1A, a target for antibody-mediated tumor therapy: its biochemical nature, tissue distribution and recognition by different monoclonal antibodies. Int J Cancer 38:47-53
20. Hainsworth JD (2002) Rituximab as first-line and maintenance therapy for patients with indolent non-Hodgkin's lymphoma: interim follow-up of a multicenter phase II trial. Semin Oncol 29:25-29
21. Hoevel T, Macek R, Mundigl O, Swisshelm K, Kubbies M (2002) Expression and targeting of the tight junction protein CLDN1 in CLDN1-negative human breast tumor cells. J Cell Physiol 191:60-68
22. Hough CD, Sherman-Baust CA, Pizer ES, Montz FJ, Im DD, Rosenshein NB, Cho KR, Riggins GJ, Morin PJ (2000) Large-scale serial analysis of gene expression reveals genes differentially expressed in ovarian cancer. Cancer Res 60:6281-6287
23. Hughes-Jones NC, Gorick BD, Howard JC, Feinstein A (1985) Antibody density on rat red cells determines the rate of activation of the complement component C1. Eur J Immunol 15:976-980
24. Katahira J, Sugiyama H, Inoue N, Horiguchi Y, Matsuda M, Sugimoto N (1997) Clostridium perfringens enterotoxin utilizes two structurally related membrane proteins as functional receptors in vivo. J Biol Chem 272:26652-26658
25. Khor SP, Saleh MN, Braddock JM, Pithavala YK, Thurmond L, Wissel PS, Bigley JW, LoBoglio AF (1997) A phase I trial of humanized monoclonal antibody 3622W94 including pharmacokinetics (PK) and immunogenicity evaluation. Proc Am Soc Clin Oncol. ASCO annual meeting (Abstract No. 847)
26. Kim JH, Herlyn D, Wong KK, Park DC, Schorge JO, Lu KH, Skates SJ, Cramer DW, Berkowitz RS, Mok SC (2003) Identification of epithelial cell adhesion molecule autoantibody in patients with ovarian cancer. Clin Cancer Res 9:4782-4791
27. Kiuchi-Saishin Y, Gotoh S, Furuse M, Takasuga A, Tano Y, Tsukita S (2002) Differential expression patterns of claudins, tight junction membrane proteins, in mouse nephron segments. J Am Soc Nephrol 13:875-886
28. Krogh A, Larsson B, von Heijne G, Sonnhammer EL (2001) Predicting transmembrane protein topology with a hidden Markov model: application to complete genomes. J Mol Biol 305:567-580
29. Kubota K, Furuse M, Sasaki H, Sonoda N, Fujita K, Nagafuchi A, Tsukita S (1999) Ca(2+)-independent cell-adhesion activity of claudins, a family of integral membrane proteins localized at tight junctions. Curr Biol 9:1035-1038
30. Litvinov SV, Velders MP, Bakker HA, Fleuren GJ, Warnaar SO (1994) Ep-CAM: a human epithelial antigen is a homophilic cell-cell adhesion molecule. J Cell Biol 125:437-446
31. Litvinov SV, Balzar M, Winter MJ, Bakker HA, Briaire-de Bruijn IH, Prins F, Fleuren GJ, Warnaar SO (1997) Epithelial cell adhesion molecule (Ep-CAM) modulates cell-cell interactions mediated by classic cadherins. J Cell Biol 139:1337-1348
32. LoBuglio AF, Saleh MN, Braddock JM, Lampkin TA, Khor SP, Wissel PS, Bigley JW (1997) A phase I trial of humanized anti-EGP40 monoclonal antibody 3622W94. Proc Am Soc Clin Oncol 16:436
33. Long H, Crean CD, Lee WH, Cummings OW, Gabig TG (2001) Expression of Clostridium perfringens enterotoxin receptors claudin-3 and claudin-4 in prostate cancer epithelium. Cancer Res 61:7878-7881
34. Mack M, Riethmuller G, Kufer P (1995) A small bispecific antibody construct expressed as a functional single-chain molecule with high tumor cell cytotoxicity. Proc Natl Acad Sci U S A 92:7021-7025
35. Madara JL (1998) Regulation of the movement of solutes across tight junctions. Annu Rev Physiol 60:143-159
36. Matter K, Balda MS (1999) Occludin and the functions of tight junctions. Int Rev Cytol 186:117-146
37. Mayer A, Tsiompanou E, O'Malley D, Boxer GM, Bhatia J, Flynn AA, Chester KA, Davidson BR, Lewis AA, Winslet MC, Dhillon AP, Hilson AJ, Begent RH (2000) Radioimmunoguided surgery in colorectal cancer using a genetically engineered anti-CEA single-chain Fv antibody. Clin Cancer Res 6:1711-1719
38. McCann FE, Suhling K, Carlin LM, Eleme K, Taner SB, Yanagi K, Vanherberghen B, French PM, Davis DM (2002) Imaging immune surveillance by T cells and NK cells. Immunol Rev 189:179-192
39. McLaughlin PM, Harmsen MC, Dokter WH, Kroesen BJ, van der Molen H, Brinker MG, Hollema H, Ruiters MH, Buys CH, de Leij LF (2001) The epithelial glycoprotein 2 (EGP-2) promoter-driven epithelial-specific expression of EGP-2 in transgenic mice: a new model to study carcinoma-directed immunotherapy. Cancer Res 61:4105-4111
40. Michl P, Buchholz M, Rolke M, Kunsch S, Lohr M, McClane B, Tsukita S, Leder G, Adler G, Gress TM (2001) Claudin-4: a new target for pancreatic cancer treatment using Clostridium perfringens enterotoxin. Gastroenterology 121:678-684
41. Mitic LL, Van Itallie CM, Anderson JM (2000) Molecular physiology and pathophysiology of tight junctions I. Tight junction structure and function: lessons from mutant animals and proteins. Am J Physiol Gastrointest Liver Physiol 279:G250-G254
42. Morita K, Furuse M, Fujimoto K, Tsukita S (1999) Claudin multigene family encoding four-transmembrane domain protein components of tight junction strands. Proc Natl Acad Sci U S A 96:511-516
43. Morita K, Sasaki H, Furuse M, Tsukita S (1999) Endothelial claudin: claudin-5/TMVCF constitutes tight junction strands in endothelial cells. J Cell Biol 147:185-194
44. Naundorf S, Preithner S, Mayer P, Lippold S, Wolf A, Hanakam F, Fichtner I, Kufer P, Raum T, Riethmuller G, Baeuerle PA, Dreier T (2002) In vitro and in vivo activity of MT201, a fully human monoclonal antibody for pancarcinoma treatment. Int J Cancer 100:101-110
45. Ogura E, Senzaki H, Yoshizawa K, Hioki K, Tsubura A (1998) Immunohistochemical localization of epithelial glycoprotein EGP-2 and carcinoembryonic antigen in normal colonic mucosa and colorectal tumors. Anticancer Res 18:3669-3675
46. Pantel K, Izbicki J, Passlick B, Angstwurm M, Haussinger K, Thetter O, Riethmuller G (1996) Frequency and prognostic significance of isolated tumour cells in bone marrow of patients with non-small-cell lung cancer without overt metastases. Lancet 347:649-653
47. Piyathilake CJ, Frost AR, Weiss H, Manne U, Heimburger DC, Grizzle WE (2000) The expression of Ep-CAM (17-1A) in squamous cell cancers of the lung. Hum Pathol 31:482-487
48. Poczatek RB, Myers RB, Manne U, Oelschlager DK, Weiss HL, Bostwick DG, Grizzle WE (1999) Ep-Cam levels in prostatic adenocarcinoma and prostatic intraepithelial neoplasia. J Urol 162:1462-1466
49. Rahner C, Mitic LL, Anderson JM (2001) Heterogeneity in expression and subcellular localization of claudins 2, 3, 4, and 5 in the rat liver, pancreas, and gut. Gastroenterology 120:411-422
50. Riethmuller G, Klein CA, Pantel K (1999) Hunting down the seminal cells of clinical metastases. Immunol Today 20:294-296
51. Rossmann ED, Lundin J, Lenkei R, Mellstedt H, Osterborg A (2001) Variability in B-cell antigen expression: implications for the treatment of B-cell lymphomas and leukemias with monoclonal antibodies. Hematol J 2:300-306
52. Saleh MN, Khazaeli LM, Thurmond LM, Khor SP, Lampkin TA, Wissel PS, LoBouglio AF (1998) Phase I trial testing multiple doses of humanized monoclonal antibody (Mab) 3622W94. Proc Am Soc Clin Oncol. ASCO annual meeting (Abstract No. 1680)
53. Schwartzberg LS (2001) Clinical experience with edrecolomab: a monoclonal antibody therapy for colorectal carcinoma. Crit Rev Oncol Hematol 40:17-24
54. Sondel PM, Hank JA, Can J, Neal Z, Albertini MR (2003) Preclinical and clinical development of immunocytokines. Curr Opin Investig Drugs 4:696-700
55. Sonoda N, Furuse M, Sasaki H, Yonemura S, Katahira J, Horiguchi Y, Tsukita S (1999) Clostridium perfringens enterotoxin fragment removes specific claudins from tight junction strands: evidence for direct involvement of claudins in tight junction barrier. J Cell Biol 147:195-204
56. Spizzo G, Obrist P, Ensinger C, Theurl I, Dunser M, Ramoni A, Gunsilius E, Eibl G, Mikuz G, Gastl G (2002) Prognostic significance of Ep-CAM AND Her-2/neu overexpression in invasive breast cancer. Int J Cancer 98:883-888
57. Steffens MG, Boerman OC, Oosterwijk-Wakka JC, Oosterhof GO, Witjes JA, Koenders EB, Oyen WJ, Buijs WC, Debruyne FM, Corstens FH, Oosterwijk E (1997) Targeting of renal cell carcinoma with iodine-131-labeled chimeric monoclonal antibody G250. J Clin Oncol 15:1529-1537
58. Terris B, Blaveri E, Crnogorac-Jurcevic T, Jones M, Missiaglia E, Ruszniewski P, Sauvanet A, Lemoine NR (2002) Characterization of gene expression profiles in intraductal papillary-mucinous tumors of the pancreas. Am J Pathol 160:1745-1754
59. Tsukita S, Furuse M (2000) Pores in the wall: claudins constitute tight junction strands containing aqueous pores. J Cell Biol 149:13-16
60. Tsukita S, Furuse M (2002) Claudin-based barrier in simple and stratified cellular sheets. Curr Opin Cell Biol 14:531-536
61. Tsukita S, Furuse M, Itoh M (1999) Structural and signalling molecules come together at tight junctions. Curr Opin Cell Biol 11:628-633
62. Velders MP, Litvinov SV, Warnaar SO, Gorter A, Fleuren GJ, Zurawski VR Jr, Coney LR (1994) New chimeric anti-pancarcinoma monoclonal antibody with superior cytotoxicity-mediating potency. Cancer Res 54:1753-1759
63. Weckermann D, Muller P, Wawroschek F, Harzmann R, Riethmuller G, Schlimok G (2001) Disseminated cytokeratin positive tumor cells in the bone marrow of patients with prostate cancer: detection and prognostic value. J Urol 166:699-703
64. Wilcox ER, Burton QL, Naz S, Riazuddin S, Smith TN, Ploplis B, Belyantseva I, Ben-Yosef T, Liburd NA, Morell RJ, Kachar B, Wu DK, Griffith AJ, Friedman TB (2001) Mutations in the gene encoding tight junction claudin-14 cause autosomal recessive deafness DFNB29. Cell 104:165-172
65. Zhang S, Zhang HS, Reuter VE, Slovin SF, Scher HI, Livingston PO (1998) Expression of potential target antigens for immunotherapy on primary and metastatic prostate cancers. Clin Cancer Res 4:295-302